ストックスクリーナーアプリを入手
0.639
3.38%
0.0209
プレマーケット:
.63
-0.009
-1.41%
前日終値:
$0.6181
開ける：
$0.6224
24時間の取引高:
40,547
Relative Volume:
0.17
時価総額：
$2.77M
収益：
$7,500
当期純損益:
$-9.84M
株価収益率:
-0.1116
EPS:
-5.7263
ネットキャッシュフロー:
$-9.25M
1週間 パフォーマンス:
+4.46%
1か月 パフォーマンス:
+13.64%
6か月 パフォーマンス:
-43.95%
1年 パフォーマンス:
-87.47%
1日の値動き範囲:
$0.61
$0.6471
1週間の範囲:
$0.57
$0.6471
52週間の値動き範囲:
$0.5038
$9.60
Oragenics Inc Stock (OGEN) Company Profile
名前
Oragenics Inc
セクター
電話
813-286-7900
住所
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Compare OGEN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.639 | 2.77M | 7,500 | -9.84M | -9.25M | -5.7263 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oragenics Inc (OGEN) 最新ニュース
Oragenics, Inc. Opens Second Clinical Site for Phase IIa Trial of ONP-002, Evaluating Treatment for Concussion with 60 Participants - geneonline.com
Oragenics Expands Phase IIa Trial for Concussion Treatment to Second Site - citybuzz -
Oragenics adds second site to concussion drug trial in Australia - Investing.com
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. - GlobeNewswire
Oragenics shares plunge following announcement of $20 million preferred stock sale - MSN
OGEN News | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics (OGEN) Advances in Phase IIa Trial for Concussion Trea - GuruFocus
Oragenics (OGEN) Advances in Phase IIa Trial for Concussion Treatment - GuruFocus
Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - The Manila Times
Concussion has no approved drug; Oragenics doses 2 in trial - Stock Titan
OGEN Stock Price, Quote & Chart | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
OGEN Ownership | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Earnings Recap: Is Oragenics Inc gaining market shareWeekly Stock Report & Weekly High Momentum Picks - baoquankhu1.vn
Oragenics Doses First Patient in Phase IIa Trial for Potential Concussion Treatment - citybuzz -
Oragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia - TipRanks
Oragenics Doses First Patient in Phase IIa Trial of ONP-002 for Concussion, Targeting Unmet Need in Mild Traumatic Brain Injury 1 - Minichart
Oragenics doses first patient in Phase IIa trial of ONP-002 for concussion - TradingView
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - GlobeNewswire
Sectors Review: Is Oragenics Inc stock technically oversold2026 Institutional & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Oragenics (OGEN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Nasdaq Moves: Is Oragenics Inc vulnerable to short sellersQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Risk On: Is Oragenics Inc gaining market sharePrice Action & Advanced Technical Signal Analysis - baoquankhu1.vn
Rally Mode: Is Oragenics Inc gaining market share2026 Trading Volume Trends & Long-Term Capital Growth Strategies - baoquankhu1.vn
Can Oragenics (OGEN) Stock Rebound in 2026 | Price at $0.61, Up 8.48%Risk Management - Newser
0A64.IL,0P0001LL1F,111 (0A64.IL) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Oragenics Inc (UAV.BE) Stock Price, News, Quote & History - ca.finance.yahoo.com
Oragenics Sets New 2025 Annual Shareholder Meeting Date - The Globe and Mail
Oragenics: CEO Highlights "Undervalued" Pipeline Amid Significant Insider Sale of 35% Ownership - Bitget
Oragenics (OGEN) schedules 2025 shareholder meeting and sets May 1, 2026 proposal cutoff - Stock Titan
Risks Report: What is the target price for Oragenics Inc stockDollar Strength & Real-Time Stock Movement Alerts - baoquankhu1.vn
Oragenics Receives Going Concern Qualification Amid Clinical Trial Preparations - citybuzz -
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - Sahm
Oragenics (OGEN) Reports Going Concern Risk in Latest Audit - GuruFocus
OGEN SEC FilingsOragenics 10-K, 10-Q, 8-K Forms - Stock Titan
Volume Recap: Is Oragenics Inc vulnerable to short sellers2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn
[EFFECT] ORAGENICS INC SEC Filing - Stock Titan
If You Invested $1,000 in Oragenics (OGEN) - Stock Titan
Growth Report: Is Oragenics Inc forming bullish engulfing patterns2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Oragenics, Inc.: Fundamental Analysis and Financial Ratings | UAV0 | US6840236094 - marketscreener.com
OGEN Forecast, Price Target & Analyst Ratings | ORAGENICS INC (NYSEARCA:OGEN) - ChartMill
Oragenics (NASDAQ: OGEN) updates S-3/A with auditor consent - Stock Titan
Oragenics Files 2025 Annual Report, Highlights Progress in Concussion Treatment Development - citybuzz -
Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates - geneonline.com
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K - The Manila Times
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oragenics Inc (OGEN) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):